TG Therapeutics Inc. (NASDAQ:TGTX)’s share price shot up 6.7% on Wednesday . The stock traded as high as $6.24 and last traded at $6.24, with a volume of 156,931 shares. The stock had previously closed at $5.85.

Several research firms have weighed in on TGTX. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research report on Monday, June 13th. Zacks Investment Research downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Brean Capital reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, May 31st. Roth Capital reaffirmed a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a research report on Thursday, June 9th. Finally, SunTrust Banks Inc. assumed coverage on TG Therapeutics in a research report on Friday, May 27th. They issued a “buy” rating and a $18.00 price objective for the company. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $22.33.

The firm’s 50-day moving average price is $6.42 and its 200 day moving average price is $8.06. The stock’s market cap is $345.55 million.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.08. On average, equities analysts forecast that TG Therapeutics Inc. will post ($1.15) EPS for the current fiscal year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund increased its position in shares of TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned approximately 0.43% of TG Therapeutics worth $2,671,000 at the end of the most recent quarter.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.